Thrombolysis in myocardial infarction (TIMI) trial-Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

Journal of the American College of Cardiology

Volumn 11, Issue 1, 1988, Pages 1-11

  Rao, A Koneti ^a   Pratt, Craig ^a   Berke, Andrew ^a   Jaffe, Allan ^a   Ockene, Ira ^a   Schreiber, Theodore L ^a   Bell, William R ^a   Knatterud, Genell ^a   Robertson, Thomas L ^a   Terrin, Michael L ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; HEPARIN; PLASMIN; PLASMINOGEN; STREPTOKINASE;

ADULT; ADVERSE DRUG REACTION; BLEEDING; DRUG THERAPY; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PLASMINOGEN ACTIVATION;

CLINICAL TRIALS; COMPARATIVE STUDY; FIBRINOGEN; FIBRINOLYSIS; HEMORRHAGE; HUMAN; MYOCARDIAL INFARCTION; RANDOM ALLOCATION; RECOMBINANT PROTEINS; STREPTOKINASE; THROMBOCYTOPENIA; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0023864355     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(88)90158-1     Document Type: Article

References (32)

1. Prevalence of total coronary occlusion during early hours of transmural myocardial infarction
2. Thrombolytic therapy in patients with acute myocardial infarction
3. Thrombolytic therapy. A new strategy for the treatment of acute myocardial infarction
4. Purification of human tissue-type plasminogen activator in centigram quantities from human melanoma cell culture fluid and its conditioning for use in vivo
5. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli
6. The Thrombolysis in Myocardial Infarction (TIMI) trial Phase I findings
7. Thrombolysis in Myocardial Infarction (TIMI) trial, Phase 1: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase
8. Micromethod for the estimation of plasma fibrinogen
9. Plasminogen determination in human plasma
10. Randomized trial of intravenous recombinart tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for recombinant tissue-type plasminogen activator
11. Fibrin: structure and interactions
12. Biological effects of fibrinogen-fibrin degradation products
13. Plasmin inhibition of platelet function and of arachidonic acid metabolism
14. Inhibition of platelet aggregation by contrast media
15. Inhibition of platelet function by contrast media: iopamidol and ioxaglate versus iothalamate
16. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI Thrombolysis in Myocardial Infarction (TIMI) Trial
17. High dose intravenous streptokinase for acute myocardial infarction: preliminary results of a multicenter trial
18. Coronary thrombolysis with recombinant tissue-type plasminogen activator. A hematologic and pharmacologic study
19. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction
20. Coronary thrombolysis with recombinant human tissue-type plasminogen activator. A prospective, randomized, placebo-controlled trial
21. Coronary thrombolysis with recombinant human tissue type plasminogen activator
22. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis
23. Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in non-human primates
24. Clot-selective coronary thrombolysis with tissue-type plasminogen activator
25. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in man
26. TIMI Investigators Plasma plasminogen activator activity in patients treated with intravenous recombinant tissue plasminogen activator and streptokinase (abstr)
27. High dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarction: description of effects in the circulation
28. Fibrinolytic effects of intracoronary streptokinase administration in patients with acute myocardial infarction and coronary insufficiency
29. Hemorrhage and the products of fibrinogen digestion after intracoronary administration of streptokinase
30. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by maintainence infusion